Annual General Meeting Alterity Therapeutics

(NASDAQ:ATHE, ASX:ATH)

David Stamler, MD

Chief Medical Officer

November 2020

Forward Looking Statements

This presentation may contain some statements that may be considered "Forward-Looking Statements", within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to the Company's plans, objectives, expectations or intentions involve risks and uncertainties that may cause actual results to differ materially. For a discussion of such risks and uncertainties as they relate to us, please refer to our 2020 Form 20-F, filed with US Securities and Exchange Commission, in particular Item 3, Section D, titled "Risk Factors.''

2

Our Purpose

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life.

We're here to disrupt the trajectory for people with these diseases.

CONFIDENTIAL

3

Year in Review

Allowance of US patent for next generation compounds to treat neurodegenerative diseases

Raises $35M in placement to international and Australian institutions and sophisticated investors

Commences enrolling Multiple System

Atrophy patients in bioMUSE Study

ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor

performance

US FDA provides development pathway for ATH434

ATH434 crosses blood brain barrier in humans; clinically tested doses achieved concentrations in the brain

European Commission approves Orphan Designation

ATH434 clinical data presented at the 2019 MDS Congress

Completion of Phase 1 Clinical Trial

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Alterity Therapeutics Ltd. published this content on 18 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 November 2020 04:44:04 UTC